Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease

Chronic kidney disease (CKD) and several other catabolic conditions are characterized by increased circulating inflammatory cytokines, defects in IGF‐1 signaling, abnormal muscle protein metabolism, and progressive muscle atrophy. In these conditions, no reliable treatments successfully block the development of muscle atrophy. In mice with CKD, we found a 2‐ to 3‐fold increase in myostatin expression in muscle. Its pharmacological inhibition by subcutaneous injections of an anti‐myostatin peptibody into CKD mice (IC 50 ~1.2 nM) reversed the loss of body weight (≈5–7% increase in body mass) and muscle mass (~10% increase in muscle mass) and suppressed circulating inflammatory cytokines vs. results from CKD mice injected with PBS. Pharmacological myostatin inhibition also decreased the rate of protein degradation (16.38±1.29%;P<0.05), increased protein synthesis in extensor digitorum longus muscles (13.21±1.09%; P<0.05), markedly enhanced satellite cell function, and improved IGF‐1 intracellular signaling. In cultured muscle cells, TNF‐α increased myostatin expression via a NF‐κB‐dependent pathway, whereas muscle cells exposed to myostatin stimulated IL‐6 production via p38 MAPK and MEK1 pathways. Because IL‐6 stimulates muscle protein breakdown, we conclude that CKD increases myostatin through cytokine‐activated pathways, leading to muscle atrophy. Myostatin antagonism might become a therapeutic strategy for improving muscle growth in CKD and other conditions with similar characteristics.—Zhang, L., Rajan, V., Lin, E., Hu, Z., Han, H.Q., Zhou, X., Song, Y., Min, H., Wang, X., Du, J., Mitch, W. E. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. 25, 1653–1663 (2011). www.fasebj.org